High-dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent progressive malignant brain tumors in children: A pilot Pediatric Oncology Group study

被引:86
作者
Mahoney, DH
Strother, D
Camitta, B
Bowen, T
Ghim, T
Pick, T
Wall, D
Yu, L
Shuster, JJ
Friedman, H
机构
[1] BROOKE ARMY MED CTR,FT SAM HOUSTON,TX 78234
[2] BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030
[3] MIDWEST CHILDRENS CANC CTR,MILWAUKEE,WI
[4] ALBERTA CHILDRENS PROV GEN HOSP,CALGARY,AB,CANADA
[5] EMORY UNIV,SCH MED,ATLANTA,GA
[6] UNIV WASHINGTON,MED CTR,ST LOUIS,MO
[7] CHILDRENS HOSP NEW ORLEANS,NEW ORLEANS,LA
[8] UNIV FLORIDA,PEDIAT ONCOL GRP,STAT OFF,GAINESVILLE,FL 32611
[9] DUKE UNIV,MED CTR,DURHAM,NC
关键词
D O I
10.1200/JCO.1996.14.2.382
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To determine the maximum-tolerated dose of cyclophosphamide (CTX) when administered sequentially with melphalan 60 mg/m(2)/d for 3 days, followed by autologous bone marrow rescue (ABMR), in children with recurrent or progressive malignant brain tumors, and to make preliminary observations on efficacy. Patients and Methods: Nineteen patients between the ages of 2 and 21 years were enrolled and 18 were assessable for effects of therapy. CTX was administered to seven patients at 750 mg/m(2)/d for 4 days, to five patients at 975 mg/m(2)/d, to three patients at 1,200 mg/m(2)/d, and to three patients at 1,500 mg/m(2)/d. All patients received ABMR. Granulocyte-macrophage colony-stimulating factor (GM-CSF) was used in 15 patients. Toxicity, response to therapy, time to progression, and survival were monitored. Results: The median time to a granulocyte count more than 500/dL was 19 days (range, 11 to 39), and for a platelet count more than 50,000/dL was 33 days (range, 16 to 60). Four heavily pretreated patients (22%) died of transplant-related complications. No dose-limiting, nonhematologic toxicities were defined for the study. Seven of 18 patients (39%) had a complete response (CR) or a partial response (PR). These included four patients with medulloblastoma (CR and three PRs), two with germinomas (two CRs), and one with ependymoma (one CR). The estimated 1-year survival rate was 39% (SE 12%). Conclusion: CTX, at a maximum total dose of 6,000 mg/m(2), administered sequentially with melphalan and followed by ABMR was tolerable in children with recurrent brain tumors who had not been heavily pretreated. Responses were seen in patients with medulloblastoma and germinomas. Further trials in children with chemosensitive tumors, with minimal residual disease, are planned. (C) 1996 by American Society of Clinical Oncology.
引用
收藏
页码:382 / 388
页数:7
相关论文
共 43 条
[1]  
ABRAHAMSEN TG, 1995, AM J PEDIAT HEMATOL, V17, P134
[2]   HIGH-DOSE CYCLOPHOSPHAMIDE CHEMOTHERAPY FOR RECURRENT CNS TUMORS IN CHILDREN [J].
ALLEN, JC ;
HELSON, L .
JOURNAL OF NEUROSURGERY, 1981, 55 (05) :749-756
[3]   CHEMOTHERAPY TRIALS IN RECURRENT PRIMARY INTRACRANIAL GERM-CELL TUMORS [J].
ALLEN, JC ;
BOSL, G ;
WALKER, R .
JOURNAL OF NEURO-ONCOLOGY, 1985, 3 (02) :147-152
[4]  
ALLEN JC, 1986, SEMIN ONCOL, V13, P110
[5]  
Ater Joann L., 1992, Cancer Bulletin (Houston), V44, P490
[6]   CYCLOPHOSPHAMIDE CARDIOTOXICITY IN BONE-MARROW TRANSPLANTATION - A PROSPECTIVE EVALUATION OF NEW DOSING REGIMENS [J].
BRAVERMAN, AC ;
ANTIN, JH ;
PLAPPERT, MT ;
COOK, EF ;
LEE, RT .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (07) :1215-1223
[7]   A PHASE-2 TRIAL OF ORAL MELPHALAN IN RECURRENT PRIMARY BRAIN-TUMORS [J].
CHAMBERLAIN, MC ;
PRADOS, MD ;
SILVER, P ;
LEVIN, VA .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1988, 11 (01) :52-54
[8]  
DUERST R, 1993, P AM SOC CLIN ONCOL, V12, P426
[9]  
EDER JP, 1989, BONE MARROW TRANSPL, V4, P57
[10]  
FINLAY J, 1994, PROG P AM SOC CLIN O, V13, P176